ASCO Annual Meeting | Conference

Dr. Bardia on Ongoing Research With Amcenestrant and Palbociclib in ER+/HER2- Advanced Breast Cancer

June 12th 2021

Aditya Bardia, MD, MPH, discusses ongoing research with amcenestrant and palbociclib in estrogen receptor–positive, HER2-negative advanced breast cancer.

Dr. Chandarlapaty on Responses to Amcenestrant/Palbociclib in ER+/HER2- Metastatic Breast Cancer

June 12th 2021

Sarat Chandarlapaty, MD, PhD, highlights responses to amcenestrant and palbociclib in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer, as seen in the phase 1/2 AMEERA 1 trial.

Dr. von Mehren on Outcomes With Ribociclib/Everolimus in Dedifferentiated Liposarcoma

June 12th 2021

Margaret von Mehren, MD, discusses outcomes with ribociclib and everolimus in dedifferentiated liposarcoma, as seen in the phase 2 SAR-096 trial.

ALLO-501A With ALLO-647 Lymphodepletion Shows Early Efficacy in Relapsed/Refractory Large B-Cell Lymphoma

June 11th 2021

Treatment with the allogeneic CAR T-cell product ALLO-501A elicited encouraging signals of clinical activity when used with ALLO-647 lymphodepletion in patients with relapsed/refractory large B-cell lymphoma who did not previously receive autologous CAR T-cell therapy.

Week 24 Transfusion Independence With Momelotinib Is Associated With Improved OS in Myelofibrosis

June 10th 2021

Week 24 transfusion independence was associated with an improvement in overall survival vs week 24 transfusion dependence in patients with myelofibrosis who were randomized to momelotinib in the phase 3 SIMPLIFY 1 and SIMPLIFY 2 trials.

Allo-Transplant Recommended for Eligible Patients With Myelofibrosis

June 10th 2021

Allogeneic hematopoietic cell transplant should be considered a standard of care option for patients with high-risk myelofibrosis, according to findings from a systematic review and meta-analysis.

Regorafenib/Pembrolizumab Combination Yields Encouraging Results in Advanced HCC

June 10th 2021

The combination of regorafenib plus pembrolizumab in the first-line setting for patients with advanced hepatocellular carcinoma showed encouraging anti-tumor activity with a disease control rate of 91%, and did not display any new safety signals.

Frontline Belzutifan Showcases Significant Clinical Activity in VHL-Associated RCC

June 9th 2021

The hypoxia-inducible factor-2 alpha inhibitor belzutifan maintained clinical efficacy with further follow-up in patients with Von-Hippel Lindau–associated renal cell carcinoma, as well as other VHL-associated neoplasms.

Regorafenib/Nivolumab Found to be More Effective in Japanese Population vs North American in CRC

June 9th 2021

Cabozantinib Exposure Not Associated With PFS, But Is Linked With Higher AEs With Cabozantinib/Nivolumab in RCC

June 9th 2021

Cabozantinib exposure was not significantly associated with progression-free survival but appeared to predict high rates of palmar-plantar erythrodysesthesia and diarrhea in patients with advanced renal cell carcinoma treated with the frontline combination of cabozantinib and nivolumab.

Lenvatinib/Pembrolizumab Yields Survival Benefit in Advanced RCC Across IMDC Risk Groups

June 9th 2021

The addition of lenvatinib to pembrolizumab elicited a notable survival benefit and improved responses over single-agent sunitinib in patients with advanced renal cell carcinoma across evaluable International Metastatic RCC Database Consortium risk subgroups.

Pembrolizumab/Cabozantinib Combo Provides Benefit in mRCC

June 9th 2021

The combination of pembrolizumab and cabozantinib induced a response in more than half of patients with metastatic renal cell carcinoma at the recommended phase 2 dose with a manageable safety profile, meeting the primary end point of a phase 1/2 trial.

Lenvatinib Plus Toripalimab and Hepatic Arterial Infusion Chemotherapy May Represent a New First-Line Option in Advanced HCC

June 9th 2021

The addition of toripalimab and hepatic arterial infusion chemotherapy to lenvatinib yielded robust, durable responses in patients with advanced hepatocellular carcinoma, and represents a potential new treatment option for patients in the first line setting.

Real-World Analysis on Second-Line Cetuximab in mCRC Reveals Factors Linked With Longer Time on Treatment, OS

June 9th 2021

In patients with metastatic colorectal cancer who received cetuximab as a second-line therapy after irinotecan or oxaliplatin-based regimens have failed, KRAS mutational status and geographical region were associated with time on treatment, while body mass index and age were linked with overall survival.

Addition of Abiraterone to ADT plus Docetaxel Yields Improvement in rPFS in De Novo mCSPC

June 9th 2021

Adding abiraterone acetate and prednisone to androgen-deprivation therapy plus docetaxel improved radiographic progression-free survival in patients with de novo metastatic castration-sensitive prostate cancer.

Subcutaneous Elranatamab Elicits Encouraging Responses in Relapsed/Refractory Myeloma

June 8th 2021

The BCMA-targeting humanized bispecific monoclonal antibody elranatamab elicited high response rates when subcutaneously delivered at higher doses in patients with relapsed/refractory multiple myeloma.

Subsequent Therapy May Impact OS Outcomes With Frontline Lenvatinib/Everolimus in RCC

June 8th 2021

Subsequent systemic therapies were found to impact overall survival outcomes with lenvatinib plus everolimus versus sunitinib in patients with advanced renal cell carcinoma who received treatment in the phase 3 CLEAR trial.

Dr. Markowski on the Safety and Efficacy of VERU-111 in mCRPC

June 8th 2021

Mark Christopher Markowski, MD, PhD, discusses the safety and efficacy of VERU-111 in patients with metastatic castration-resistant prostate cancer.

Talquetamab at RP2D Elicits High Clinical Response Rate in Relapsed/Refractory Multiple Myeloma

June 8th 2021

Talquetamab, when delivered at the recommended phase 2 dose of 405 µg/kg weekly, induced a high clinical response rate with favorable tolerabilty in patients with relapsed/refractory multiple myeloma.

TAK-700 Plus ADT Significantly Improves PFS and PSA Responses in mHSPC, But Not OS

June 8th 2021

The addition of TAK-700 to androgen-deprivation therapy improved median progression-free survival and prostate-specific antigen responses, but did not significantly improve overall survival vs ADT and bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer.